Search
Abdavomeran
go.drugbank.com/drugs/DB15695Investigationalfibritin to increase immunogenicity. … [L15012] The modRNA is formulated in lipid nanoparticles for delivery via intramuscular injection.
Categories: Experimental Unapproved Treatments for COVID-19Felypressin
go.drugbank.com/drugs/DB00093InvestigationalIt is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth … A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two
AEOL-10150
go.drugbank.com/drugs/DB05874ExperimentalAEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Categories: Heterocyclic Compounds with 4 or More RingsHuman Menstrual Blood-derived Stem Cells
go.drugbank.com/drugs/DB15738InvestigationalESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity. … Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.
Carbenoxolone
go.drugbank.com/drugs/DB02329ExperimentalIt is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Nitrazepam
go.drugbank.com/drugs/DB01595ApprovedA benzodiazepine derivative used as an anticonvulsant and hypnotic.
Tanespimycin
go.drugbank.com/drugs/DB05134InvestigationalIt is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia. … Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).
SYNB1020
go.drugbank.com/drugs/DB17667InvestigationalIt was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.
CY-1503
go.drugbank.com/drugs/DB17605InvestigationalCY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl